Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 1999;23(2):179–189. doi: 10.1023/A:1020297213702

Lysophosphatidylcholine Abrogates the CR1 Preserving Effect of Surfactant on Quartz-Exposed Human Granulocytes

G Zetterberg 1, T Curstedt 2, J Lundahl 3, A Eklund 1
PMCID: PMC7101607  PMID: 10213273

Abstract

The effects of pulmonary surfactant on granulocytes were studied by flow cytofluorometry. Cells from hemolyzed blood were first activated by N-formyl-methionyl-leucyl-phenylalanine (fMLP) which mobilizes complement receptor 1 (CR1) from the intracellular pool to the cell surface. The reduced CR1 expression observed after quartz incubation was abolished by a porcine surfactant preparation containing phospholipids and the hydrophobic surfactant proteins. Phospholipids alone had no preservative capacity. However, addition of the surfactant proteins to the phospholipids did not restore the CR1 values to that of intact surfactant, probably due to changed protein structure during the purification procedure. Heating of surfactant at 37°C up to 72 h reduced the preservative effect of surfactant on CR1 expression. Congruent results of CR1 expression were achieved when 1–10% lysophosphatidylcholine was added to the surfactant preparations. Our results imply that lysophosphatidylcholine formed during storage of surfactant at elevated temperatures influences CR1 expression on granuloyctes.

Keywords: Quartz, Cell Surface, Elevated Temperature, Purification Procedure, Surfactant Protein

REFERENCES

  • 1.Hohlfeld J., Fabel H., Hamm H. The role of pulmonary surfactant in obstructive airways disease. Eur. Respir. J. 1997;10:482–491. doi: 10.1183/09031936.97.10020482. [DOI] [PubMed] [Google Scholar]
  • 2.Johansson J., Curstedt T., Robertson B. The proteins of the surfactant system. Eur. Respir. J. 1994;7:372–391. doi: 10.1183/09031936.94.07020372. [DOI] [PubMed] [Google Scholar]
  • 3.Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: An international randomized clinical trial. Pediatrics. 1988;82:683–691. [PubMed] [Google Scholar]
  • 4.Halliday H. L. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs. 1996;51(2):226–237. doi: 10.2165/00003495-199651020-00004. [DOI] [PubMed] [Google Scholar]
  • 5.Thomassen M. J., Meeker D. P., Antal J. M., Connors M. J., Wiedemann H. P. Synthetic surfactant (Exosurf) inhibits endotoxin-stimulated cytokine secretion by human alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 1992;7:257–260. doi: 10.1165/ajrcmb/7.3.257. [DOI] [PubMed] [Google Scholar]
  • 6.O'Neill S., Lesperance E., Klass D. J. Rat lung lavage surfactant enhances bacterial phagocytosis and intracellular killing by alveolar macrophages. Am. Rev. Respir. Dis. 1984;130:225–230. doi: 10.1164/arrd.1984.130.2.225. [DOI] [PubMed] [Google Scholar]
  • 7.Herting E., Sun B., Jarstrand C., Curstedt T., Robertson B. Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia. Arch. Dis. Child. 1997;76:F3–F8. doi: 10.1136/fn.76.1.f3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.van Iwaarden J. F., van Strijp J. A. G., Ebskamp M. J. M., Welmers A. C., Verhoef J., van Golde L. M. G. Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type 1 by rat alveolar macrophages. Am. J. Physiol. 1991;261:L204–L209. doi: 10.1152/ajplung.1991.261.2.L204. [DOI] [PubMed] [Google Scholar]
  • 9.Wallace W. E., Keane M. J., Vallyathan V., Hathaway P., Regad E. D., Castranova V., Green F. H. Y. Suppression of inhaled particle cytotoxicity by pulmonary surfactant and re-toxification by phospholipase: Distinguishing properties of quartz and kaolin. Ann. Occup. Hyg. 1988;32(suppl.1):291–298. [Google Scholar]
  • 10.Schimmelpfeng J., Drosselmeyer E., Hofheinz V., Seidel A. Influence of surfactant components and exposure geometry on the effects of quartz and asbestos on alveolar macrophages. Environ. Health Perspect. 1992;97:225–231. doi: 10.1289/ehp.9297225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wilsher M. L., Parker D. J., Haslam P. L. Immunosuppression by pulmonary surfactant: Mechanisms of action. Thorax. 1990;45:3–8. doi: 10.1136/thx.45.1.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Allen J. N., Moore S. A., Pope-Harman A. L., Marsh C. B., Wewers M. D. Immunosuppressive properties of surfactant and plasma on alveolar macrophages. J. Lab. Clin. Med. 1995;125:356–369. [PubMed] [Google Scholar]
  • 13.Walti H., Polla B. S., Bachelet M. Modified natural porcine surfactant inhibits superoxide anions and proinflammatory mediators released by resting and stimulated human monocytes. Pediatr. Res. 1997;41:114–119. doi: 10.1203/00006450-199701000-00018. [DOI] [PubMed] [Google Scholar]
  • 14.Stankus R. P., Banks D. E. Immunologic alterations in silicosis. Semin. Respir. Med. 1984;5:282–288. [Google Scholar]
  • 15.Lundahl J, Dahlgren C., Eklund A., Hed J., Hernbrand R., Tornling G. Quartz selectively down-regulates CR1 on activated human granulocytes. J. Leukoc. Biol. 1993;53:99–103. doi: 10.1002/jlb.53.1.99. [DOI] [PubMed] [Google Scholar]
  • 16.Berger M., Weltzler E. M., Welter E., Turner J. R., Tartakoff A. M. Intracellular sites for storage and recycling of C3b receptors in human neutrophils. Proc. Natl. Acad. Sci. U.S.A. 1991;88:3019–3023. doi: 10.1073/pnas.88.8.3019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Piddlesden S. J., Storch M. K., Hibbs M., Freeman A. M., Lassmann H., Morgan B. P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 1994;152:5477–5484. [PubMed] [Google Scholar]
  • 18.Zetterberg G., Lundahl J., Curstedt T., Eklund A. Surfactant prevents quartz induced down-regulation of complement receptor 1 in human granulocytes. Inflammation. 1997;21:83–92. doi: 10.1023/a:1027394926261. [DOI] [PubMed] [Google Scholar]
  • 19.Robertson B., Curstedt T., Johansson J., JÖrnvall H., Kobayashi T. Structural and functional characterization of porcine surfactant isolated by liquid-gel chromatography. Prog. Respir. Res. 1990;25:237–246. [Google Scholar]
  • 20.Curstedt T., JÖrnvall H., Robertson B., Bergman T., Berggren P. Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant. Characterization and biophysical activity. Eur. J. Biochem. 1987;168:255–262. doi: 10.1111/j.1432-1033.1987.tb13414.x. [DOI] [PubMed] [Google Scholar]
  • 21.Speer C. P., GÖtze B., Curstedt T., Robertson B. Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf) Pediatr. Res. 1991;30:69–74. doi: 10.1203/00006450-199107000-00015. [DOI] [PubMed] [Google Scholar]
  • 22.Lundahl J., Dahlgren C., Gustavsson K., Hed J. Serum protects against azurophil granule dependent down-regulation of complement receptor type 1 (CR1) on human neutrophils. Inflamm. Res. 1995;44:438–446. doi: 10.1007/BF01757701. [DOI] [PubMed] [Google Scholar]
  • 23.Possmayer F. A proposed nomenclature for pulmonary surfactant-associated proteins. Am. Rev. Respir. Dis. 1988;138:990–998. doi: 10.1164/ajrccm/138.4.990. [DOI] [PubMed] [Google Scholar]
  • 24.Persson A., Chang D., Rust K., Moxley M., Longmore W., Crouch E. Purification and biochemical characterization of CP4 (SP-D), a collagenous surfactant-associated protein. Biochemistry. 1989;28:6361–6367. doi: 10.1021/bi00441a031. [DOI] [PubMed] [Google Scholar]
  • 25.Gustafsson M., Curstedt T., JÖrnvall H., Johansson J. Reverse-phase HPLC of the hydrophobic pulmonary surfactant proteins: Detection of a surfactant protein C isoform containing Nε-palmitoyl-lysine. Biochem. J. 1997;326:799–806. doi: 10.1042/bj3260799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Johansson J., Nilsson G., StrÖmberg R., Robertson B., JÖrnvall H., Curstedt T. Secondary structure and biophysical activity of synthetic analogues of the pulmonary surfactant polypeptide SP-C. Biochem. J. 1995;307:535–541. doi: 10.1042/bj3070535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Liau D. F., Yin N. X., Huang J., Ryan S. F. Effects of human polymorphonuclear leukocyte elastase upon surfactant proteins in vitro. Biochim. Biophys. Acta. 1996;1302:117–128. doi: 10.1016/0005-2760(96)00042-2. [DOI] [PubMed] [Google Scholar]
  • 28.Ryan S. F., Ghassibi Y., Liau D. F. Effects of activated polymorphonuclear leukocytes upon pulmonary surfactant in vitro. Am. J. Respir. Cell Mol. Biol. 1991;4(1):33–41. doi: 10.1165/ajrcmb/4.1.33. [DOI] [PubMed] [Google Scholar]
  • 29.Jarstrand C., Wiernik A., Curstedt T., Sundqvist K. G. Lung surfactant inhibits the lipopolysaccharide induced release of oxygen radicals, enzymes and interleukin-1 from phagocytes. Immunol. & Infect. Dis. 1991;1:179–182. [Google Scholar]
  • 30.Kuhn D. C., Demers L. M. Effect of surfactant on basal and silica-induced eicosanoid production by alveolar macrophages. Am. J. Physiol. 1995;269:L165–L170. doi: 10.1152/ajplung.1995.269.2.L165. [DOI] [PubMed] [Google Scholar]
  • 31.Tegtmeyer F. K., Gortner L., Ludwig A., Brandt E. In vitro modulation of induced neutrophil activation by different surfactant preparations. Eur. Respir. J. 1996;9:752–757. doi: 10.1183/09031936.96.09040752. [DOI] [PubMed] [Google Scholar]
  • 32.Curstedt, T., J. Johansson, B. Robertson, P. Persson, B. LÖwenadler, and H. JÖrnvall. 1993. Structure and function of hydrophobic surfactant-associated proteins. In: Surfactant in clinical practice, edited by G. Bevilaqua, S. Parmigiani, and B. Robertson. Harwood, Chur. pp. 55–60.
  • 33.Fornasier M., Puccini P., Razzetti R., Acerbi D., Bongrani S., Ventura P. Evaluation of potentially injurious effects of exogenous surfactant lysophospholipids on the alveolar epithelium and pulmonary mechanics. Biol. Neonate. 1997;71:337–344. doi: 10.1159/000244433. [DOI] [PubMed] [Google Scholar]

Articles from Inflammation are provided here courtesy of Nature Publishing Group

RESOURCES